Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Manojkumar Patel

Pulmonary Disease Chesapeake, VA Medical Doctor

NPI 1396953469 CMS profile 63026

725 Volvo Pkwy, Ste 102, Chesapeake, VA 23320

Open in the dashboard

General payments

$10,658

531 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Manojkumar Patel of Chesapeake, VA is reported in the CMS Open Payments database as having received $10,658 across 531 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,288 100
2024 General $1,725 69
2023 General $1,739 77
2022 General $1,214 57
2021 General $1,001 63
2020 General $1,339 74
2019 General $1,352 91

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Manojkumar Patel
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Manojkumar Patel were reported at $2,288. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Manojkumar Patel Pulmonary Disease median Middle half National median
2019 $1,352 $377 $109–$1,340 $163
2020 $1,339 $230 $56–$907 $114
2021 $1,001 $269 $68–$1,072 $132
2022 $1,214 $390 $100–$1,457 $149
2023 $1,739 $419 $114–$1,659 $160
2024 $1,725 $476 $123–$1,818 $164
2025 $2,288 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $1,918 112 payments
  2. AstraZeneca Pharmaceuticals LP $1,099 56 payments
  3. Genzyme Corporation $862 41 payments
  4. ANI Pharmaceuticals, Inc. $528 18 payments
  5. Actelion Pharmaceuticals US, Inc. $464 19 payments
  6. Mallinckrodt Hospital Products Inc. $449 22 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $441 21 payments
  8. Grifols USA, LLC $326 12 payments
  9. Mylan Specialty L.P. $324 23 payments
  10. Philips Electronics North America Corporation $316 24 payments
  11. Other $3,930 183 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,217 525 payments
  2. Education $441 6 payments
Products named General payments · program years 2019–2025
  1. NUCALA $941 44 payments
  2. DUPIXENT $846 38 payments
  3. TRELEGY ELLIPTA $636 41 payments
  4. PURIFIED CORTROPHIN GEL $450 15 payments
  5. ACTHAR $449 22 payments
  6. FASENRA $416 17 payments
  7. UPTRAVI $402 16 payments
  8. SPIRIVA RESPIMAT $357 19 payments
  9. OPSUMIT $338 14 payments
  10. Prolastin-C Liquid $326 12 payments
  11. Other $7,283 374 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,354

Median for Pulmonary Disease: 936

Drug cost

$499,359

Median for Pulmonary Disease: $487,987

Branded share of claims

57.5%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 136 $130,440
Spiriva Respimat Tiotropium Bromide Brand 68 $71,898
Xolair Omalizumab Brand 19 $52,035
Nucala Mepolizumab Brand 14 $51,421
Dupixent Pen Dupilumab Brand 14 $50,538
Breo Ellipta Fluticasone/Vilanterol Brand 85 $43,347
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 16 $16,421
Eliquis Apixaban Brand 19 $14,970
Advair Hfa Fluticasone Propion/Salmeterol Brand 25 $11,874
Tiotropium Bromide Generic 20 $11,177

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$275,490

Medicare's payments for the services billed

Medicare patients

879

Average age 75

Services billed

2,840

435 women, 444 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 53%
Arthritis 52%
Ischemic heart disease 47%
Diabetes 43%
Heart failure 39%
Chronic kidney disease 34%
Atrial fibrillation 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PURIFIED CORTROPHIN GEL
$294 — —
DUPIXENT
$139 14 —
NUCALA
$135 14 —
WAKIX
$127 — —
TEZSPIRE
$118 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

531 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record